Liminatus Pharma (LIMN) Stock: Buy, Sell, or Hold?
LIMN - Liminatus Pharma, Inc. Class A Common Stock
$3.90
0.15 (4.00%)
â˛
5d:
-7.03%
30d:
+1.56%
90d:
+2634.92%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When LIMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LIMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LIMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LIMN is currently trading at $3.90, which is considered fair relative to its 30-day fair value range of $3.50 to $4.23.
Technical Outlook: Technically, LIMN is in a strong uptrend. Immediate support is located at $3.56, while resistance sits at $4.48. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: LIMN scores 9/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LIMN is in a strong uptrend. Immediate support is located at $3.56, while resistance sits at $4.48. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: LIMN scores 9/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.50 -
$4.23
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (9/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.50 -
$4.23
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.56
Resistance Level
$4.48
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 02, 2026 5:26 PM ET
Data refreshes hourly during market hours. Next update: 6:26 PM
Data refreshes hourly during market hours. Next update: 6:26 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LIMN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 50 HOLD |